Smart insulin systems may shield hearts in type 1 diabetes

NCT ID NCT07241702

Ongoing Disease control Sponsor: Attikon Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether hybrid closed-loop systems (automated insulin pumps) can improve heart and blood vessel health in adults with type 1 diabetes. Researchers will compare these systems to standard insulin injections or added SGLT2 inhibitor drugs. They will measure artery stiffness, heart function, and blood vessel health over 12 months in 100 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hybrid closed-loop system (automated insulin delivery device)
What this could lead to: If successful, this could show that automated insulin systems protect the heart and blood vessels better than standard insulin injections in type 1 diabetes.
What could go wrong: This is a small, non-randomized observational study, so results may not prove cause and effect. The devices are already available, so the main question is whether they offer extra heart benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

Attikon University General Hospital

Athens, 12462, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.